MicroRNA-focused CRISPR/Cas9 screen identifies miR-142 as a key regulator of Epstein-Barr virus reactivation
PLOS Pathogens · 2024
DOI: 10.1371/journal.ppat.1011970 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2024. Verfasst von Yan Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America. Hauptthemen laut MEDLINE: Herpesvirus 4, Human, MicroRNAs, Virus Activation, Epstein-Barr Virus Infections. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Reactivation from latency plays a significant role in maintaining persistent lifelong Epstein-Barr virus (EBV) infection. Mechanisms governing successful activation and progression of the EBV lytic phase are not fully understood. EBV expresses multiple viral microRNAs (miRNAs) and manipulates several cellular miRNAs to support viral infection. To gain insight into the host miRNAs regulating transitions from EBV latency into the lytic stage, we conducted a CRISPR/Cas9-based screen in EBV+ Burkitt lymphoma (BL) cells using anti-Ig antibodies to crosslink the B cell receptor (BCR) and induce reactivation. Using a gRNA library against >1500 annotated human miRNAs, we identified miR-142 as a key regulator of EBV reactivation. Genetic ablation of miR-142 enhanced levels of immediate early and early lytic gene products in infected BL cells. Ago2-PAR-CLIP experiments with reactivated cells revealed miR-142 targets related to Erk/MAPK signaling, including components directly downstream of the B cell receptor (BCR). Consistent with these findings, disruption of miR-142 enhanced SOS1 levels and Mek phosphorylation in response to surface Ig cross-linking. Effects could be rescued by inhibitors of Mek (cobimetinib) or Raf (dabrafenib). Taken together, these results show that miR-142 functionally regulates SOS1/Ras/Raf/Mek/Erk signaling initiated through the BCR and consequently, restricts EBV entry into the lytic cycle.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.
ORCID-Profile: Rebecca L Skalsky
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Chen, Y., Kincaid, R. P., Bastin, K., Fachko, D. N., & Skalsky, R. L. (2024). MicroRNA-focused CRISPR/Cas9 screen identifies miR-142 as a key regulator of Epstein-Barr virus reactivation. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011970
Vancouver
Chen Y, Kincaid RP, Bastin K, Fachko DN, Skalsky RL. MicroRNA-focused CRISPR/Cas9 screen identifies miR-142 as a key regulator of Epstein-Barr virus reactivation. PLOS Pathogens. 2024. doi:10.1371/journal.ppat.1011970
BibTeX
@article{Chen2024,
author = {Chen, Yan and Kincaid, Rodney P and Bastin, Kelley and Fachko, Devin N and Skalsky, Rebecca L},
title = {MicroRNA-focused CRISPR/Cas9 screen identifies miR-142 as a key regulator of Epstein-Barr virus reactivation},
journal = {PLOS Pathogens},
year = {2024},
doi = {10.1371/journal.ppat.1011970}
}
EUVIMED